GlobalData on MSN6d
Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants
French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, ...
FiercePharma6d
With amped up manufacturing effort, Sanofi and AZ look to avoid Beyfortus shortfalls this year
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
The Pharma Letter6d
Sanofi shipping RSV jab Beyfortus in USA
French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...
BioPharma Dive6d
Sanofi readies to meet US demand for RSV antibody
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...
Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts
Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...
Nasdaq3d
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Sanofi recently launched some interesting new products with the most important being novel recombinant factor VIII therapy, Altuviiio and Beyfortus/nirsevimab antibody for respiratory syncytial ...